13Z,16Z-Docosadienoic Acid
(Synonyms: 顺13,16-二十二碳二烯酸,cis-13,16-Docosadienoic Acid) 目录号 : GC16693A natural ω-6 PUFA
Cas No.:17735-98-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
13Z,16Z-Docosadienoic acid is a natural ω-6 polyunsaturated fatty acid (PUFA) formed through a 2-carbon chain elongation of arachi donic acid. 13Z,16Z-Docosadienoic acid acts as an agonist of free fatty acid receptor 4 (FFAR4, also known as GPR120) [1].
Free fatty acids act as a source of energy and also function as signaling molecules which involved in regulating energy homeostasis. The endogenous ligands for FFAR4 are ω3-FAs, such as α-LA,DHA and EPA. FFAR4 has been involved in diverse physiological process such as anti-inflammation, insulin sensitization, release of gut peptides and alternation of food preference [2].
13Z,16Z-Docosadienoic acid strongly inhibited the secretion of ghrelin by isolated mouse gastric cells [1]. Dietary n-3 polyunsaturated fatty acids (PUFA) ameliorate several human diseases such as coronary heart disease, autoimmune and inflammatory disorders, diabetes, obesity and cancer [3]. This 20:2 PUFA has already been identified in fish, mammals, plants, and anaerobic fungi.
References:
[1]. X. Lu, X. Zhao, J. Feng, et al. Postprandial inhibition of gastric ghrelin secretion by long-chain fatty acid through GPR120 in isolated gastric ghrelin cells and mice. Am. J. Physiol. Gastrointest. Liver Physiol. 303(3), G367-376 (2012).
[2]. Kimura I. Omega-3 fatty acids and FFAR4[J]. Obesity and Diabetes: Energy Regulation by Free Fatty Acid Receptors, 2016: 29.
[3]. Ma D W L, Seo J, Switzer K C, et al. n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research[J]. The Journal of nutritional biochemistry, 2004, 15(11): 700-706.
| Cas No. | 17735-98-7 | SDF | |
| 别名 | 顺13,16-二十二碳二烯酸,cis-13,16-Docosadienoic Acid | ||
| 化学名 | 13Z,16Z-docosadienoic acid | ||
| Canonical SMILES | CCCCC/C=C\C/C=C\CCCCCCCCCCCC(O)=O | ||
| 分子式 | C22H40O2 | 分子量 | 336.6 |
| 溶解度 | ≤10mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9709 mL | 14.8544 mL | 29.7089 mL |
| 5 mM | 0.5942 mL | 2.9709 mL | 5.9418 mL |
| 10 mM | 0.2971 mL | 1.4854 mL | 2.9709 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。